Cargando…
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TKIs), there is a need for additional therapeutic ap...
Autores principales: | Howe, Grant A., Xiao, Bin, Zhao, Huijun, Al-Zahrani, Khalid N., Hasim, Mohamed S., Villeneuve, James, Sekhon, Harmanjatinder S., Goss, Glenwood D., Sabourin, Luc A., Dimitroulakos, Jim, Addison, Christina L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786279/ https://www.ncbi.nlm.nih.gov/pubmed/26962872 http://dx.doi.org/10.1371/journal.pone.0150567 |
Ejemplares similares
-
Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non–Small Cell Lung Carcinoma Cells()()
por: Bar, Jair, et al.
Publicado: (2016) -
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
por: Goss, Glenwood D., et al.
Publicado: (2016) -
Activating Transcription Factor 3 as a Novel Regulator of Chemotherapy Response in Breast Cancer()()
por: Hasim, Mohamed S., et al.
Publicado: (2018) -
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer
por: Feng, Rui, et al.
Publicado: (2016) -
Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic
por: Goss, Glenwood D., et al.
Publicado: (2022)